The page cannot be displayed because you are using Internet Explorer version 8 or lower.

Please consider upgrading your browser here

We use cookies on this website. By using the website you accept our use of cookies. Accept


EASD-Novo Nordisk Foundation Diabetes Prize for Excellence

Professor Gökhan Hotamışlıgil received the 2018 EASD–Novo Nordisk Foundation Diabetes Prize for Excellence for his outstanding research efforts that have led to groundbreaking new knowledge about the relationship between obesity and diabetes and potential paths for treatment.


New knowledge on diabetes

The EASD–Novo Nordisk Foundation Diabetes Prize for Excellence is awarded to recognize outstanding research or technology contributions to the understanding of diabetes, its disease mechanisms or its complications.

The Prize is accompanied by DKK 6 million – of which DKK 1 million is a personal award and the remaining DKK 5 million is for research purposes.

The Prize is awarded to an internationally recognized researcher who has contributed significantly to diabetes research. The Prize winner’s research may focus on prevention, treatment and/or basic research in physiological biochemistry. The research may also be clinically oriented. In addition, the Prize may be awarded for the “discovery of the decade” within diabetes research.

The following are further selection criteria.

  • The primary criterion in the selection process is a scientific contribution to diabetes research (understanding, prevention, diagnosis or treatment).
  • Only employees of universities, hospitals or other non-profit institutions will be considered.
  • Candidates must be highly renowned and may be from any country.

The Prize is awarded in collaboration between the European Association for the Study of Diabetes (EASD) and the Novo Nordisk Foundation. A special prize award committee appointed by the EASD decides the winner of the Prize, and the Novo Nordisk Foundation donates the money accompanying the Prize.

Attended by about 18,000 diabetes researchers from more than 130 countries, EASD rotates its annual scientific meeting between various cities and towns. The Prize is conferred at the meeting.

- EASD is proud to join forces with the Novo Nordisk Foundation in recognizing those actively fighting to stop one of the defining health problems of the 21st century, says . Andrew J.M. Boulton, President, European Association for the Study of Diabetes.

Scientific excellence

Globally, more than 370 million people have diabetes, and this number is expected to increase to 550 million in 2030. This makes the disease one of the most pressing global health problems.

With the establishment of the Prize, the Novo Nordisk Foundation also strives to reward and encourage individual scientific excellence in order to promote innovative research that can lead to new knowledge about diabetes for the benefit of people with diabetes and stimulate interest in science and technology in society as a whole.


News room